
Oncology NEWS International
- Oncology NEWS International Vol 11 No 11
- Volume 11
- Issue 11
Taxoprexin Pivotal Studies Begin in Melanoma and Pancreatic Cancer
KING OF PRUSSIA, Pennsylvania-Protarga, Inc. has received comments from the FDA that allow it to proceed with two separate phase III clinical studies of its new cancer drug Taxoprexin Injection (DHA-pacli-taxel) for the treatment of metastatic melanoma and pancreatic cancer. Taxoprexin is made by linking the fatty acid docosahexaenoic acid (DHA) to paclitaxel, the company said in a news release.
KING OF PRUSSIA, PennsylvaniaProtarga, Inc. has received comments from the FDA that allow it to proceed with two separate phase III clinical studies of its new cancer drug Taxoprexin Injection (DHA-pacli-taxel) for the treatment of metastatic melanoma and pancreatic cancer. Taxoprexin is made by linking the fatty acid docosahexaenoic acid (DHA) to paclitaxel, the company said in a news release.
Articles in this issue
almost 24 years ago
Zoledronic Acid Reduces SREs in Solid Tumorsalmost 24 years ago
Study Supports Wider Use of SLN Biopsy in Breast Canceralmost 24 years ago
Minorities Less Likely Than Whites to Receive Good Pain Carealmost 24 years ago
Polyglutamate-Paclitaxel Controls Recurrent Ovarian Canceralmost 24 years ago
9cRA Shown to Reverse Premaliagnant Changes in Ex-Smokersalmost 24 years ago
FDA Names New ODAC Chairalmost 24 years ago
Neoadjuvant Weekly Paclitaxel Effective in Advanced Breast Canceralmost 24 years ago
Docetaxel Plus Gemcitabine Promising in Advanced Pancreatic Canceralmost 24 years ago
Polysaccharides Unique Targets for Immunotherapyalmost 24 years ago
Genetic Fingerprinting Shows Distinct Sarcoma Subsets
















































